Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Receivables - Net: 2020-2025

  • Kymera Therapeutics' Receivables - Net was N/A to $40.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $40.0 million, marking a year-over-year change of. This contributed to the annual value of $15.0 million for FY2023, which is N/A change from last year.
  • Latest data reveals that Kymera Therapeutics reported Receivables - Net of $40.0 million as of Q2 2025, which was up 166.67% from $15.0 million recorded in Q4 2023.
  • Kymera Therapeutics' Receivables - Net's 5-year high stood at $40.0 million during Q2 2025, with a 5-year trough of $900,000 in Q1 2021.
  • In the last 2 years, Kymera Therapeutics' Receivables - Net had a median value of $27.5 million in 2023 and averaged $27.5 million.